Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

I would like to be an EHA Guest

Would you like to connect with EHA, but you do not feel ready to fully commit yet? By becoming an EHA Guest, you will enjoy:

Free access to the European Hematology Curriculum
Limited access the EHA Campus
Receive EHA Newsflashes to keep you informed…

Read more

Dr A van Hylckama Vlieg Announced Winner of the first EHA-ISTH Joint Fellowship

The award of EUR 72,000 over two years is intended to support the study of the physiology of bleeding, coagulation or thrombosis. Dr.

Read more

EHA mapping of adolescent and young adult (AYA) hematology patient care

EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.

Read more

Statement

The European Hematology Association (EHA), a dedicated community of healthcare professionals, who work tirelessly "Towards prevention, cure, and quality of life for all patients with blood disorders", expresses its deep concern and sorrow over the ongoing violence and humanitarian crisis…

Read more

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more

EMA Issues Call for Expressions of Interest for Drug Safety Studies

The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.

Read more